(Q36642042)

15 August 2017

1 reference

title

A cost-effectiveness approach to the qualification and acceptance of biomarkers (English)

1 reference

cost-effectiveness analysis

15 August 2017

0 references

1 reference

Stephen A Williams

1

1 reference

15 August 2017

David E Slavin

series ordinal

2

1 reference

15 August 2017

John A Wagner

series ordinal

3

1 reference

15 August 2017

Christopher J Webster

series ordinal

4

1 reference

15 August 2017

publication date

1 November 2006

1 reference

Nature Reviews Drug Discovery

15 August 2017

published in

1 reference

15 August 2017

volume

5

1 reference

15 August 2017

issue

11

1 reference

15 August 2017

page(s)

897-902

1 reference

https://scigraph.springernature.com/pub.10.1038/nrd2174

15 August 2017

exact match

0 references

cites work

Surrogate endpoints in clinical trials: definition and operational criteria

1 reference

Biomarkers and surrogate markers: an FDA perspective

21 January 2018

1 reference

Surrogate endpoints: a basis for a rational approach

21 January 2018

1 reference

Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies

21 January 2018

1 reference

A new approach to risk evaluation and management: risk-based, precaution-based, and discourse-based strategies

21 January 2018

1 reference

21 January 2018

1 reference

Fewer new drugs from the pharmaceutical industry

21 January 2018

1 reference

Drug-related hepatotoxicity

21 January 2018

1 reference

Carotid intimal-media thickness as a surrogate for cardiovascular disease events in trials of HMG-CoA reductase inhibitors

21 January 2018

1 reference

How safe is safe enough? A psychometric study of attitudes towards technological risks and benefits

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1038/NRD2174

1 reference

Dimensions Publication ID

15 August 2017

1034368121

0 references

1 reference